285 related articles for article (PubMed ID: 10397541)
21. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
22. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.
Marimoutou C; Chêne G; Mercié P; Neau D; Farbos S; Morlat P; Ceccaldi J; Dabis F;
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):161-7. PubMed ID: 11404538
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
[TBL] [Abstract][Full Text] [Related]
25. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
Yasuda JM; Miller C; Currier JS; Forthal DN; Kemper CA; Beall GN; Tilles JG; Capparelli EV; McCutchan JA; Haubrich RH;
Antivir Ther; 2004 Oct; 9(5):753-61. PubMed ID: 15535413
[TBL] [Abstract][Full Text] [Related]
26. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
[TBL] [Abstract][Full Text] [Related]
27. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
28. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
[TBL] [Abstract][Full Text] [Related]
29. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
31. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
[TBL] [Abstract][Full Text] [Related]
32. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
[TBL] [Abstract][Full Text] [Related]
33. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
35. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy.
Haubrich RH; Currier JS; Forthal DN; Beall G; Kemper CA; Johnson D; Dubé MP; Hwang J; Leedom JM; Tilles J; McCutchan JA;
Clin Infect Dis; 2001 Oct; 33(7):1060-8. PubMed ID: 11528581
[TBL] [Abstract][Full Text] [Related]
36. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
[TBL] [Abstract][Full Text] [Related]
37. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
Paterson DL; Swindells S; Mohr J; Brester M; Vergis EN; Squier C; Wagener MM; Singh N
Ann Intern Med; 2000 Jul; 133(1):21-30. PubMed ID: 10877736
[TBL] [Abstract][Full Text] [Related]
38. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
[TBL] [Abstract][Full Text] [Related]
39. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM
AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590
[TBL] [Abstract][Full Text] [Related]
40. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]